Menu
Not yet recruiting NCT07570628

Implementation of a Clinical Decision Support System in Primary Care for the Screening and Assessment of Frailty in Patients Aged 65 and Over

Observational Frailty at Older Adults Primary Care Geriatric Assessment Implementation Research

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Frailty at Older Adults, Primary Care, Geriatric Assessment, Implementation Research. Basic parameters: from 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Implementation of a Clinical Decision Support System in Primary Care for the Screening and Assessment of Frailty in Patients Aged 65 and Over: A Real-World Prospective Cohort Study

Overview

This observational study aims to evaluate the real-life use of a digital tool (Fragiclic) by general practitioners (GPs) and nurses to screen and assess frailty in adults aged 65 and over. Frailty is a syndrome that increases the risk of loss of autonomy, falls, hospitalizations, or death. The tool includes simple screening questionnaires (such as SEGAm) and a comprehensive assessment (CGA - Comprehensive Geriatric Assessment) to better manage patients' health. The main question it aims to answer is: * What proportion of patients aged 65 and over will benefit from frailty screening or assessment using Fragiclic over 12 months? A secondary question is \- Does the use of Fragiclic reduce the risk of unplanned hospitalizations or death in these patients? For the secondary question, researchers will compare patients who received screening or assessment (with or without a Personalized Care Plan (PCP)) to those who did not, to determine if Fragiclic improves their health outcomes. Participants will not have additional tasks: Their GP or nurse will use Fragiclic during routine consultations. Some patients may be asked to provide information about their health or quality of life (via their healthcare provider). All data will be collected anonymously and securely

Primary outcome measures

  • Proportion of patients who have benefited from at least one screening or frailty assessment associated with a personalized care plan [Time frame: From patient enrollment to the end of follow-up at 12+/-1 months]
Secondary outcome measures (5)
  • Rates of all-cause mortality and unplanned hospitalizations among patients included in the study [Time frame: From patient enrollment to the end of follow-up at 12+/-1 months]
  • Number, percentage, and type of personalized care plans prescribed based on the tool used and the degree of PCP implementation [Time frame: at 3 months after prescription]
  • Acceptability of the use of the Fragiclic platform among healthcare professionals (HCP) who are users and non-users [Time frame: at the end of patients follow-up, 12 months after enrollment]
  • Socio-demographic profiles of healthcare professionals (HCP) who are users and non-users (age, gender, mode of practice) and usage profiles (number of logins, SEGAm, EGS, and PPS completed, average usage duration) [Time frame: at the end of patients follow-up, 12 months after enrollment]
  • Number and percetange of complete implementation (patients with complete screening or assessment: complete frailty assessment grid and complete PPS) [Time frame: at the end of patients follow-up, 12 months after enrollment]

Eligibility criteria

Inclusion criteria

  • Patients aged 65 years or older
  • Patient or trusted person who provided oral non-opposition after receiving full information about the protocol
  • Managed by the general practitioner if the patient or nurse during the study period. If patients are assessed by a nurse : Patients whose general practitioner is a participating physician in the study

Exclusion criteria

  • Patients unable to express non-opposition or without a trusted person available to express non-opposition
  • Patients whose general practitioner (GP) is not a participating GP in the study
  • Patients or trusted persons who do not speak French

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

France · 1 center
  • MSPU Torcy — Torcy

Identifiers

NCT: NCT07570628 · 2025-A00640-49

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗